Glenmark likely to out licence GRC 10693

2009 April 18

Pharma major Glenmark is likely to out licence GRC 10693, reports CNBC-TV18 quoting sources. The company is likely to receive upfront payment of up to $ 40 million.

Glenmark has completed Phase I trial of GRC 10693 in Europe. GRC 10693 is a pain relieving drug. Glen Saldanha speaking to CNBC-TV18 said that the company is in active conversation to out licence GRC 10693

Related posts:

  1. Glenmark Pharmaceuticals Limited issue closed yesterday Glenmark Pharmaceuticals Limited Institutional qualified placement (Kyuaipi) issue closed yesterday. The company was opened...

Comments are closed for this entry.